[go: up one dir, main page]

CN116179492A - 一种胰腺癌类器官无血清专用培养基 - Google Patents

一种胰腺癌类器官无血清专用培养基 Download PDF

Info

Publication number
CN116179492A
CN116179492A CN202310234880.8A CN202310234880A CN116179492A CN 116179492 A CN116179492 A CN 116179492A CN 202310234880 A CN202310234880 A CN 202310234880A CN 116179492 A CN116179492 A CN 116179492A
Authority
CN
China
Prior art keywords
medium
culture
pancreatic cancer
serum
cancer organoids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310234880.8A
Other languages
English (en)
Inventor
郭诗翔
杨佳丽
张峻烽
陶俊宇
潘红梅
秦凡博
王槐志
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chongqing General Hospital
Original Assignee
Chongqing General Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chongqing General Hospital filed Critical Chongqing General Hospital
Priority to CN202310234880.8A priority Critical patent/CN116179492A/zh
Publication of CN116179492A publication Critical patent/CN116179492A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

本发明提供一种胰腺癌类器官无血清专用培养基，涉及器官培养皿技术领域。该胰腺癌类器官无血清专用培养基，包括基础培养基和培养添加物，所述基础培养基为含有1％B—内酰胺类抗生素、1％HEPES缓冲液、1％GlutaMax溶液的DMEM/F12培养基，所述培养添加物包括TGF‑β、TNF‑α、EGF、PDGF、VEGF、FGF、IL‑1、IL‑6，含壳聚糖纳米粒子，CD3抗体和TLR7/8激动剂，所述培养添加物的终浓度为TGF‑β：0.01‑0.08μg/mL，TNF‑α：0.02‑0.09μg/mL，EGF：0.04‑0.1μg/mL，PDGF：0.05‑0.08μg/mL，VEGF；0.06‑0.1μg/mL，FGF：0.02‑0.08μg/mL，IL‑1：0.01‑0.05μg/mL，IL‑6：0.03‑0.07μg/mL。通过在基础培养基中加入一些含壳聚糖纳米粒子、CD3抗体和TLR7/8激动剂，能够使生物活性增强，提高促进类器官细胞增殖、细胞存活率以及细胞的生长和增殖，提高该培养基的实用性。

Description

一种胰腺癌类器官无血清专用培养基
技术领域
本发明涉及器官培养皿技术领域，具体为一种胰腺癌类器官无血清专用培养基。
背景技术
胰腺癌的预后极差，五年总生存率仅为10％左右。目前的治疗措施如吉西他滨、紫杉醇或奥沙利铂应答率很低，复发极为常见。此外，胰腺癌的隐匿进展和转移也是预后不良的主要原因。因此，迫切需要工具和模型来为个别患者确定更有效的治疗方案。随着分子生物学技术的进展，已经知道胰腺癌是一种高度异质性疾病，包括不同的亚型，这些亚型在遗传表型、病理特征和临床表现均不相同，因此构建基于患者来源的肿瘤体外模型，能够准确模拟体内肿瘤的生物学特征和对药物治疗的反应，对于肿瘤研究、药物测试及筛选有着巨大的价值，利用胰腺癌患者来源的肿瘤组织建立个体化的类器官肿瘤模型，为患者筛选敏感的化疗药物或靶向药物，是胰腺癌个体化治疗的一个重要途，类器官是细胞的三维组装体，包含一种以上的细胞类型，能够至少表现出细胞所述器官的生理特性。由于其保持了亲本肿瘤的关键特征，可以利用类器官进行药物筛选、预测患者放化疗反应等。
目前在对胰腺癌类器官无血清培养基的培养过程中，大多数都是采用传统的方法，例如在培养基中添加Wnt激动剂R-spond i n、BMP抑制剂Noggi n等调控因子，但是在传统的方法中，培养基中的生物活性较差，导致整个培养基的培养效率较慢，花费的较多，导致其实用性降低。
发明内容
(一)解决的技术问题
针对现有技术的不足，本发明提供了一种胰腺癌类器官无血清专用培养基，解决了传统的培养基中的生物活性较差，导致整个培养基的培养效率较慢，花费的较多，导致其实用性降低的问题。
(二)技术方案
为实现以上目的，本发明通过以下技术方案予以实现：一种胰腺癌类器官无血清专用培养基，包括基础培养基和培养添加物，所述基础培养基为含有1％B—内酰胺类抗生素、1％HEPES缓冲液、1％G l utaMax溶液的DMEM/F12培养基，所述培养添加物包括TGF-β、TNF-α、EGF、PDGF、VEGF、FGF、I L-1、I L-6，含壳聚糖纳米粒子，CD3抗体和TLR7/8激动剂。
优选的，所述培养添加物的终浓度为TGF-β：0.01-0.08μg/mL，TNF-α：0.02-0.09μg/mL，EGF：0.04-0.1μg/mL，PDGF：0.05-0.08μg/mL，VEGF；0.06-0.1μg/mL，FGF：0.02-0.08μg/mL，I L-1：0.01-0.05μg/mL，I L-6：0.03-0.07μg/mL，含壳聚糖纳米粒子：0.03-0.1μg/mL，CD3抗体：0.02-0.06μg/mL，TLR7/8激动剂：0.01-0.05μg/mL。
优选的，所述基础培养基为无血清培养基。
优选的，所述在配制好的基础培养基中，按照终浓度加入所有培养添加物，混合均匀后即可获得。
一种胰腺癌类器官的培养方法：
将胰腺癌组织样本处理清洗后加入胶原酶消化，然后将消化后的细胞重悬于冷的Cu ltrexTMgrowthfactorreducedBMEtype2中，接种于细胞培养板，待含有细胞的BME固化后，加入1-4所述的一种胰腺癌类器官无血清专用培养基进行培养。
(三)有益效果
本发明提供了一种胰腺癌类器官无血清专用培养基。具备以下有益效果：
本发明中，通过在基础培养基中加入一些含壳聚糖纳米粒子、CD3抗体和TLR7/8激动剂，能够使生物活性增强，提高促进类器官细胞增殖、细胞存活率以及细胞的生长和增殖，提高该培养基的实用性。
具体实施方式
下面将结合本发明实施例，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
实施例一：
本发明实施例提供一种胰腺癌类器官无血清专用培养基，包括基础培养基和培养添加物，基础培养基为无血清培养基，基础培养基为含有1％B—内酰胺类抗生素、1％HEPES缓冲液、1％G l utaMax溶液的DMEM/F12培养基，培养添加物包括TGF-β、TNF-α、EGF、PDGF、VEGF、FGF、I L-1、I L-6，含壳聚糖纳米粒子，CD3抗体和TLR7/8激动剂，培养添加物的终浓度为TGF-β：0.01μg/mL，TNF-α：0.02μg/mL，EGF：0.04μg/mL，PDGF：0.05μg/mL，VEGF；0.06-μg/mL，FGF：0.02μg/mL，I L-1：0.01μg/mL，I L-6：0.03μg/mL，含壳聚糖纳米粒子：0.03μg/mL，CD3抗体：0.02μg/mL，TLR7/8激动剂：0.01μg/mL，在配制好的基础培养基中，按照终浓度加入所有培养添加物，混合均匀后即可获得。
一种胰腺癌类器官的培养方法：
将胰腺癌组织样本处理清洗后加入胶原酶消化，将消化后的细胞重悬于冷的CultrexTMgrowthfactorreducedBMEtype2中，接种于细胞培养板，待含有细胞的BME固化后，加入1-4的一种胰腺癌类器官无血清专用培养基进行培养，放入5％CO2浓度、37℃细胞培养箱培养，每4～6天更换一次上述培养基，7天左右即可获得所需胰腺癌类器官。
实施例二：
本发明实施例提供一种胰腺癌类器官无血清专用培养基，包括基础培养基和培养添加物，基础培养基为无血清培养基，基础培养基为含有1％B—内酰胺类抗生素、1％HEPES缓冲液、1％G l utaMax溶液的DMEM/F12培养基，培养添加物包括TGF-β、TNF-α、EGF、PDGF、VEGF、FGF、I L-1、I L-6，含壳聚糖纳米粒子，CD3抗体和TLR7/8激动剂，培养添加物的终浓度为TGF-β：0.08μg/mL，TNF-α：0.09μg/mL，EGF：0.1μg/mL，PDGF：0.08μg/mL，VEGF；0.1μg/mL，FGF：0.08μg/mL，I L-1：0.05μg/mL，I L-6：0.07μg/mL，含壳聚糖纳米粒子：0.1μg/mL，CD3抗体：0.06μg/mL，TLR7/8激动剂：0.05μg/mL，在配制好的基础培养基中，按照终浓度加入所有培养添加物，混合均匀后即可获得。
一种胰腺癌类器官的培养方法：
将胰腺癌组织样本处理清洗后加入胶原酶消化，将消化后的细胞重悬于冷的CultrexTMgrowthfactorreducedBMEtype2中，接种于细胞培养板，待含有细胞的BME固化后，加入1-4的一种胰腺癌类器官无血清专用培养基进行培养，放入5％CO2浓度、37℃细胞培养箱培养，每4～6天更换一次上述培养基，7天左右即可获得所需胰腺癌类器官。
尽管已经示出和描述了本发明的实施例，对于本领域的普通技术人员而言，可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型，本发明的范围由所附权利要求及其等同物限定。

Claims (5)

1.一种胰腺癌类器官无血清专用培养基，其特征在于，包括基础培养基和培养添加物，所述基础培养基为含有1％B—内酰胺类抗生素、1％HEPES缓冲液、1％GlutaMax溶液的DMEM/F12培养基，所述培养添加物包括TGF-β、TNF-α、EGF、PDGF、VEGF、FGF、IL-1、IL-6，含壳聚糖纳米粒子，CD3抗体和TLR7/8激动剂。
2.根据权利要求1所述的一种胰腺癌类器官无血清专用培养基，其特征在于：所述培养添加物的终浓度为TGF-β：0.01-0.08μg/mL，TNF-α：0.02-0.09μg/mL，EGF：0.04-0.1μg/mL，PDGF：0.05-0.08μg/mL，VEGF；0.06-0.1μg/mL，FGF：0.02-0.08μg/mL，IL-1：0.01-0.05μg/mL，IL-6：0.03-0.07μg/mL，含壳聚糖纳米粒子：0.03-0.1μg/mL，CD3抗体：0.02-0.06μg/mL，TLR7/8激动剂：0.01-0.05μg/mL。
3.根据权利要求1所述的一种胰腺癌类器官无血清专用培养基，其特征在于：所述基础培养基为无血清培养基。
4.根据权利要求1所述的一种胰腺癌类器官无血清专用培养基，其特征在于：所述在配制好的基础培养基中，按照终浓度加入所有培养添加物，混合均匀后即可获得。
5.一种胰腺癌类器官的培养方法，其特征在于：将胰腺癌组织样本处理清洗后加入胶原酶消化，将消化后的细胞重悬于冷的CultrexTMgrowthfactorreducedBMEtype2中，接种于细胞培养板，待含有细胞的BME固化后，加入1-4所述的一种胰腺癌类器官无血清专用培养基进行培养。
CN202310234880.8A 2023-03-13 2023-03-13 一种胰腺癌类器官无血清专用培养基 Pending CN116179492A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310234880.8A CN116179492A (zh) 2023-03-13 2023-03-13 一种胰腺癌类器官无血清专用培养基

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310234880.8A CN116179492A (zh) 2023-03-13 2023-03-13 一种胰腺癌类器官无血清专用培养基

Publications (1)

Publication Number Publication Date
CN116179492A true CN116179492A (zh) 2023-05-30

Family

ID=86450569

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310234880.8A Pending CN116179492A (zh) 2023-03-13 2023-03-13 一种胰腺癌类器官无血清专用培养基

Country Status (1)

Country Link
CN (1) CN116179492A (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013208104A (ja) * 2012-03-02 2013-10-10 Yamaguchi Univ 消化器系がん幹細胞を培養するための無血清培地、及びそれを用いた消化器系がん幹細胞の増殖方法
US20170275592A1 (en) * 2014-11-27 2017-09-28 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
CN115094027A (zh) * 2022-07-27 2022-09-23 郑维越 一种胰腺癌类器官无血清专用培养基
JP2022181076A (ja) * 2021-05-25 2022-12-07 国立大学法人広島大学 がんオルガノイドの製造方法、評価方法および培養キット
CN115516012A (zh) * 2020-02-11 2022-12-23 诺和席卓股份有限公司 壳聚糖衍生物的新合成方法及其用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013208104A (ja) * 2012-03-02 2013-10-10 Yamaguchi Univ 消化器系がん幹細胞を培養するための無血清培地、及びそれを用いた消化器系がん幹細胞の増殖方法
US20170275592A1 (en) * 2014-11-27 2017-09-28 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
CN115516012A (zh) * 2020-02-11 2022-12-23 诺和席卓股份有限公司 壳聚糖衍生物的新合成方法及其用途
JP2022181076A (ja) * 2021-05-25 2022-12-07 国立大学法人広島大学 がんオルガノイドの製造方法、評価方法および培養キット
CN115094027A (zh) * 2022-07-27 2022-09-23 郑维越 一种胰腺癌类器官无血清专用培养基

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
张叔人: "《肿瘤免疫治疗进展》", vol. 1, 30 April 2017, 中国协和医科大学出版社, pages: 74 *
汤新之等: "《临床生物化学》", vol. 1, 31 May 1999, 《临床生物化学》, pages: 690 *

Similar Documents

Publication Publication Date Title
Yao et al. Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine
CN112080472B (zh) 一种培养专用于生物医药功能研究的人肺癌类器官3d模型的方法
Jiang et al. Organoids: opportunities and challenges of cancer therapy
EP2981273B1 (en) Compositions and methods for induction and modulation of angiogenesis and methods and assays for identifying angiogenesis modulators
CN111411084A (zh) 一种用于构建肝肿瘤无支架类器官的培养基及培养方法
CN114891748B (zh) 一种甲状腺癌类器官的培养基及甲状腺癌类器官的培养方法
CN108504625B (zh) 一种小鼠成纤维细胞及其用途
Sun et al. Immune niches orchestrated by intestinal mesenchymal stromal cells lining the crypt-villus
CN114634909A (zh) 乳腺癌类器官培养的培养基及培养方法
CN118726262A (zh) 一种肿瘤类器官的培养方法
Miao et al. Establishment of gastric cancer organoid and its application in individualized therapy
Yan et al. 3D bioprinting lobule-like hepatorganoids with induced vascularization for orthotopic implantation
CN118460471A (zh) 宫颈神经内分泌癌类器官及其培养基与培养方法
CN105861441B (zh) 一种来源于人肝细胞癌癌旁组织的肝癌细胞系stl-c1及其建系方法
Lv et al. 4D-printed hydrogel with precise regulation of viability and environment of stem cells for diabetic skin wound healing
CN116536265A (zh) 一种肝癌专用的类器官培养基、培养方法与传代方法
Wang et al. Dll4/Notch1 signalling pathway is required in collective invasion of salivary adenoid cystic carcinoma
CN116179492A (zh) 一种胰腺癌类器官无血清专用培养基
Lei et al. HnRNPAB promotes pancreatic ductal adenocarcinoma extravasation and liver metastasis by stabilizing MYC mRNA
CN114561340A (zh) 一种培养复发乳腺癌类器官的培养基及其应用
Nasiraee et al. An agarose-alginate microfluidic device for the study of spheroid invasion, ATRA inhibits CAFs-mediated matrix remodeling
CN114958753B (zh) 一种舌癌类器官的培养基、培养方法及鉴定方法
CN114794016B (zh) 一种构建肠道菌群分布紊乱和抗肿瘤免疫能力失调模型的方法
KR102719564B1 (ko) 두경부암 오가노이드의 제조방법 및 이의 용도
CN114438032B (zh) 一种用于喉癌组织3d培养的组合物、培养基及方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20230530

RJ01 Rejection of invention patent application after publication